Literature DB >> 22541791

Evaluation of the usefulness of six commercial agglutination assays for serologic diagnosis of toxoplasmosis.

Odile Villard1, Bernard Cimon, Jacqueline Franck, Hélène Fricker-Hidalgo, Nadine Godineau, Sandrine Houze, Luc Paris, Hervé Pelloux, Isabelle Villena, Ermanno Candolfi.   

Abstract

Six agglutination tests for detecting Toxoplasma gondii-specific antibodies (immunoglobulin G or M) in serum were performed and compared. In total, 599 sera were examined using direct and indirect agglutination assays. Sensitivity varied from 93.7% to 100% and specificity from 97.1% to 99.2%. In a selected population with interfering diseases, the percentage of false positives ranged from 4.3% to 10.9%. Although an overall agreement of 100% was found for chronic toxoplasmosis, sensitivity for the detection of confirmed acute toxoplasmosis ranged from 86.4% to 97.3%. Regarding the large variability in terms of the performance of the 6 assays, tests based on the hemagglutination principle were found to be better than the other agglutination tests for all the panels evaluated, meaning that they could be used as qualitative or semiquantitative low-cost screening assays.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22541791     DOI: 10.1016/j.diagmicrobio.2012.03.014

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  Help in the Choice of Automated or Semiautomated Immunoassays for Serological Diagnosis of Toxoplasmosis: Evaluation of Nine Immunoassays by the French National Reference Center for Toxoplasmosis.

Authors:  O Villard; B Cimon; C L'Ollivier; H Fricker-Hidalgo; N Godineau; S Houze; L Paris; H Pelloux; I Villena; E Candolfi
Journal:  J Clin Microbiol       Date:  2016-10-12       Impact factor: 5.948

2.  Comparison of four commercially available avidity tests for Toxoplasma gondii-specific IgG antibodies.

Authors:  O Villard; L Breit; B Cimon; J Franck; H Fricker-Hidalgo; N Godineau; S Houze; L Paris; H Pelloux; I Villena; E Candolfi
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

3.  Ocular cytokinome is linked to clinical characteristics in ocular toxoplasmosis.

Authors:  Alejandra de-la-Torre; Alexander W Pfaff; Michael E Grigg; Odile Villard; Ermanno Candolfi; Jorge E Gomez-Marin
Journal:  Cytokine       Date:  2014-04-16       Impact factor: 3.861

4.  Seroepidemiology of Toxoplasma gondii Infection in Blood Donors from Western Romania.

Authors:  Maria Alina Lupu; Rodica Lighezan; Ana Alexandra Paduraru; Angela Dragomir; Radu Pavel; Sebastian Grada; Alin Gabriel Mihu; Sorin Ursoniu; Tudor Rares Olariu
Journal:  Microorganisms       Date:  2022-05-05

5.  Performance of the BioPlex 2200 flow immunoassay in critical cases of serodiagnosis of toxoplasmosis.

Authors:  Nicolas Guigue; Jean Menotti; Samia Hamane; Francis Derouin; Yves Jean-François Garin
Journal:  Clin Vaccine Immunol       Date:  2014-01-29

6.  Anti-Toxoplasma IgG assays: What performances for what purpose? A systematic review.

Authors:  Florence Robert-Gangneux; Hélène Guegan
Journal:  Parasite       Date:  2021-04-26       Impact factor: 3.000

Review 7.  Detection of microorganisms in granulomas that have been formalin-fixed: review of the literature regarding use of molecular methods.

Authors:  Jeannette Guarner
Journal:  Scientifica (Cairo)       Date:  2012-12-31

8.  Evaluation of Serological and Molecular Tests Used for the Identification of Toxoplasma gondii Infection in Patients Treated in an Ophthalmology Clinic of a Public Health Service in São Paulo State, Brazil.

Authors:  Fernando Henrique Antunes Murata; Mariana Previato; Fábio Batista Frederico; Amanda Pires Barbosa; Fabiana Nakashima; Geraldo Magela de Faria; Aparecida Perpétuo Silveira Carvalho; Cristina da Silva Meira Strejevitch; Vera Lucia Pereira-Chioccola; Lilian Castiglioni; Luiz Carlos de Mattos; Rubens Camargo Siqueira; Cinara Cássia Brandão de Mattos
Journal:  Front Cell Infect Microbiol       Date:  2020-02-07       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.